Answers are grounded in this paper and cite their sources.
Review highlights ctDNA's role in recurrence prediction in colorectal and lung cancers, suggesting benefits for personalized therapy.
Recent advances in liquid biopsy technologies, particularly circulating tumor DNA (ctDNA) analysis, have enabled the sensitive and non-invasive detection of molecular residual disease (MRD) in solid tumors. This review summarizes the current clinical evidence and applications of MRD monitoring in solid cancers, focusing on colorectal cancer and non-small cell lung cancer (NSCLC). Tumor-informed and tumor-uninformed ctDNA assays are compared, highlighting their respective advantages and limitations. Landmark studies such as the DYNAMIC and GALAXY trials in colorectal cancer, and the TRACERx study in NSCLC, have demonstrated the prognostic value of ctDNAbased MRD detection for recurrence risk stratification and for guiding adjuvant therapy decisions. Ongoing research and standardization efforts are expected to further establish MRD assessment as an integral component of precision oncology.
No takes yet. Share an insight, caveat, or question.
Sung Hee Lim (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: